Gapping up
In reaction to earnings/guidance:
- IRNT +10%, JKS +1.1%, SKIL +1%
Other news:
- BPTS +10.7% (reports second interim analysis efficacy results in the promising zone allowing continuation of Phase 2/3 COVA Study)
- HOOK +5.6% (entered into a clinical collaboration and supply agreement with Merck & Co. (MRK))
- SAGE +5.5% (receives Fast Track Designation for SAGE-718)
- OPGN +4.7% (clinical data from an investigator-initiated and driven prospective randomized controlled multicenter study)
- BGNE +3.3% (BRUKINSA (zanubrutinib) receives accelerated approval from FDA for treatment of marginal zone lymphoma)
- OBSV +3% (submits NDA to FDA for Linzagolix)
- AFG +2.7% (declares a special dividend of $4.00/sh)
- JAMF +2.2% (prices $325.0 mln of Convertible Senior Notes due 2026)
- MRCY +2.1% (successfully demonstrates Sensor Open Systems Architecture aligned sensor processing platform at US Army)
- REGN +2% (awarded $2.9 bln Army contract; also receives US Gov't agreement to purchase 1.4 mln additional doses of REGEN-COV)
- YOU +1.9% (announces strategic partnership with Tappit)
- IDEX +1.9% (increases stake in Energica Motor Company)
- FTCI +1.7% (CEO to step down, replacement named)
- MSFT +1.2% (raises dividend by 11%; approves new $60 bln share repurchase)
Analyst comments:
- SRPT +2.8% (upgraded to Buy from Neutral at Guggenheim)
- KNX +2.4% (upgraded to Outperform from Market Perform at Cowen)
- SNDR +2.2% (upgraded to Outperform from Market Perform at Cowen)
- WERN +1.7% (upgraded to Outperform from Market Perform at Cowen)